These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28793061)

  • 1. Contemporary challenges on access to medicines: beyond the UNSG High-Level Panel.
    Bermudez J
    Cien Saude Colet; 2017 Aug; 22(8):2435-2439. PubMed ID: 28793061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respecting the right to access to medicines: Implications of the UN Guiding Principles on Business and Human Rights for the pharmaceutical industry.
    Moon S
    Health Hum Rights; 2013 Jun; 15(1):E32-43. PubMed ID: 25006088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
    Lee JY; Hunt P
    J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How the MDGs gave up on measuring access to medicines.
    Gotham D; Onarheim KH; Barber MJ
    Lancet Glob Health; 2016 May; 4(5):e296-7. PubMed ID: 27102189
    [No Abstract]   [Full Text] [Related]  

  • 5. Accelerated access to innovative medicines for patients in need.
    Baird LG; Banken R; Eichler HG; Kristensen FB; Lee DK; Lim JC; Lim R; Longson C; Pezalla E; Salmonson T; Samaha D; Tunis S; Woodcock J; Hirsch G
    Clin Pharmacol Ther; 2014 Nov; 96(5):559-71. PubMed ID: 25006877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoting innovation and access to quality, safe, efficacious, and affordable medicines for children: A China approach on the 69
    Zhang L; Li B; Liu Z; Li M; Zheng H; Sun Y
    J Evid Based Med; 2017 May; 10(2):70-75. PubMed ID: 28452205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to health care as a human right in international policy: critical reflections and contemporary challenges.
    Castillo CHM; Garrafa V; Cunha T; Hellmann F
    Cien Saude Colet; 2017 Jul; 22(7):2151-2160. PubMed ID: 28723997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration.
    Hogerzeil HV; Liberman J; Wirtz VJ; Kishore SP; Selvaraj S; Kiddell-Monroe R; Mwangi-Powell FN; von Schoen-Angerer T;
    Lancet; 2013 Feb; 381(9867):680-9. PubMed ID: 23410612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The morally uncomfortable global drug gap.
    Cohen-Kohler JC
    Clin Pharmacol Ther; 2007 Nov; 82(5):610-4. PubMed ID: 17898710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making right to health a reality in India.
    Kumar R
    Indian J Public Health; 2007; 51(3):142-4. PubMed ID: 18229437
    [No Abstract]   [Full Text] [Related]  

  • 12. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
    Burci GL; Gostin LO
    JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
    [No Abstract]   [Full Text] [Related]  

  • 13. Implications of bilateral free trade agreements on access to medicines.
    Correa CM
    Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combating counterfeit medicines and illicit trade in tobacco products: minefields in global health governance.
    Liberman J
    J Law Med Ethics; 2012; 40(2):326-47. PubMed ID: 22789049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Powerful Ideas for Global Access to Medicines.
    Moon S
    N Engl J Med; 2017 Feb; 376(6):505-507. PubMed ID: 28099819
    [No Abstract]   [Full Text] [Related]  

  • 16. Why the MDGs need good governance in pharmaceutical systems to promote global health.
    Kohler JC; Mackey TK; Ovtcharenko N
    BMC Public Health; 2014 Jan; 14():63. PubMed ID: 24447600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure.
    Jung Y; Kwon S
    Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective.
    Ahmadiani S; Nikfar S
    Daru; 2016 May; 24(1):13. PubMed ID: 27141958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protection of the access to medicines right among disabled people.].
    Puzin SN; Grechko AV; Prianikov IV; Malichenko VS; Puzin SS
    Adv Gerontol; 2018; 31(4):581-587. PubMed ID: 30607924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing the impact of economic sanctions on Iranian drug shortages in the joint comprehensive plan of action: promoting access to medicines and health diplomacy.
    Setayesh S; Mackey TK
    Global Health; 2016 Jun; 12(1):31. PubMed ID: 27267898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.